Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Talecris Biotherapeutics makes appointment

This article was originally published in Scrip

Executive Summary

Talecris Biotherapeutics (US) has named Drayton Virkler senior director of its investor relations department. He began his new position this month having served as director for US product management at Talecris's Hypermune franchise, which develops products to treat and prevent a range of potentially fatal infections. Before joining Talecris, Mr Virkler spent five years at GlaxoSmithKline in positions of increasing responsibility, including senior product manager for the migraine marketing team and product director for Advair (salmeterol plus fluticasone) marketing.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts